BioSpace News Archive

Today, the largest nationwide SARS-CoV-2 seroprevalence survey, funded by the CDC and supported by 17 blood collection organizations representing blood donations from across all 50 states, Washington D.C., and Puerto Rico, published its latest findings in the Journal of the American Medical Association (JAMA).

Establishment Labs Holdings Inc. (NASDAQ: ESTA), held a symposium at the London Breast Meeting on Thursday, September 2, 2021, marking the official launch of the company’s Motiva Flora® tissue expander in Europe and other CE Mark countries

Revenue for the quarter ended June 30, 2021 was $17.1 million compared to $13.5 million for the quarter ended June 30, 2020, an increase of $3.6 million or 26.7%.

The use of robotics and computer navigation in spinal surgery is rapidly expanding. Increasing numbers of hospitals and spine surgeons are adopting the technology, which aims to enhance precision, accuracy and predictability, according to Darren R. Lebl, MD, MBA, a spine surgeon at Hospital for Special Surgery (HSS).

American Regent, Inc. introduces FDA-approved Multrys™ (trace elements injection 4*, USP).

BioCryst Pharmaceuticals, Inc. announced that the compensation committee of BioCryst’s board of directors granted 18 newly-hired employees inducement options to purchase an aggregate of 199,000 shares of BioCryst common stock on August 31, 2021 and September 1, 2021 as inducements material to each employee entering into employment with BioCryst.

As part of a new National Institutes of Health (NIH) coronavirus disease 2019 (COVID-19) vaccine clinical trial, The Feinstein Institutes for Medical Research – the science arm of Northwell Health – delivered its first set of extra shots to eligible New York patients with an autoimmune disease.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, announced Linda Shapiro Manning, M.D., Ph.D., Senior Vice President, Clinical, will be promoted to Chief Medical Officer effective September 10, 2021.

Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that Carole Ben-Maimon, MD, President and Chief Executive Officer of Larimar Therapeutics, will present and participate in 1x1 investor meetings at the Morgan Stanley 19th Annual Global Healthcare Conference.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, announced that the company will participate in two upcoming investor conferences.